Altamira Therapeutics Ltd.
Financial ratios & Valuation

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-11.80-10.62-2.43-2.16-1.24-1.37-1.70-1.26-0.15-0.19N/A-1.24
Price/Sales ratio
71.33-4.71K-180.56164.0111.26-162.7779.97343.1113.35N/AN/A-162.77
Price/Book Value ratio
4.027.055.28-24.423.901.510.831.72-0.490.22N/A1.51
Price/Cash Flow ratio
-11.11-10.98-2.53-2.17-1.07-1.08-2.88-1.60-0.47-0.12N/A-1.07
Price/Free Cash Flow ratio
-10.44-10.95-2.51-2.16-0.94-0.79-1.94-1.28-0.37-0.12N/A-0.94
Price/Earnings Growth ratio
0.56-0.260.840.050.010.01-0.080.33-0.010.00N/A0.01
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
100%100%100%100%100%100%100%-3407.33%-372.44%N/AN/A100%
Operating Profit Margin
-737.58%46086.56%7300.30%-7565.60%-865.25%12962.75%-3028.03%-26767.77%-8550.75%N/AN/A-865.25%
Pretax Profit Margin
-604.35%44335.82%7437.99%-7586.10%-895.27%12188.81%-4712.10%-27188.48%-8683.68%N/AN/A-895.27%
Net Profit Margin
-604.35%44335.82%7406.34%-7580.58%-908.08%11842.68%-4699.90%-27222.32%-8680.30%N/AN/A-908.08%
Effective Tax Rate
4.90%0.28%0.42%0.07%-1.43%2.83%0.25%-0.12%0.03%N/AN/A-1.43%
Return on Assets
-30.56%-56.24%-85.99%-136.92%-116.39%-71.88%-39.42%-92.31%-420.90%-94.48%N/A-116.39%
Return On Equity
-34.12%-66.39%-216.80%1128.91%-315.00%-109.87%-48.89%-136.88%319.05%-112.56%N/A-315.00%
Return on Capital Employed
-40.31%-66.19%-113.19%-329.17%-206.12%-104.47%-29.73%-122.33%397.33%-86.93%N/A-206.12%
Liquidity Ratios
Current Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Quick Ratio
12.958.353.761.521.34434.95122.040.600.131.37N/A434.95
Cash ratio
12.828.143.621.431.180.603.710.200.000.69N/A0.60
Days of Sales Outstanding
11.07-3.54K-190.99N/AN/AN/AN/A124.247.79N/AN/AN/A
Days of Inventory outstanding
N/AN/AN/AN/AN/AN/AN/A136.712.94N/AN/AN/A
Operating Cycle
N/AN/AN/AN/AN/AN/AN/A260.9610.73N/AN/AN/A
Days of Payables Outstanding
N/AN/AN/AN/AN/AN/AN/A577.401.20KN/AN/AN/A
Cash Conversion Cycle
N/AN/AN/AN/AN/AN/AN/A-316.43-1.19KN/AN/AN/A
Debt Ratios
Debt Ratio
N/AN/A0.340.560.14N/A0.02N/A0.93N/AN/AN/A
Debt Equity Ratio
N/AN/A0.87-4.680.39N/A0.03N/A-0.70N/AN/AN/A
Long-term Debt to Capitalization
N/AN/A0.411.63N/AN/AN/AN/AN/AN/AN/AN/A
Total Debt to Capitalization
N/AN/A0.461.270.28N/A0.03N/A-2.40N/AN/AN/A
Interest Coverage Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow to Debt Ratio
N/AN/A-2.38-2.39-9.21N/A-9.24N/A-1.47N/AN/A-9.21
Company Equity Multiplier
1.111.182.52-8.242.701.521.241.48-0.751.19N/A1.52
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
-6.41428.7671.14-75.39-10.45149.88-27.76-214.03-28.41N/AN/A-10.45
Free Cash Flow / Operating Cash Flow Ratio
1.061.001.001.001.141.351.471.241.241N/A1.35
Cash Flow Coverage Ratio
N/AN/A-2.38-2.39-9.21N/A-9.24N/A-1.47N/AN/A-9.21
Short Term Coverage Ratio
N/AN/A-13.31-5.34-9.21N/A-9.24N/A-1.47N/AN/A-9.21
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A